长期服用保列治的疗效观察

目的观察中长期服用保列治的疗效。方法观察单独服用保列治5 mg qd并超过3年以上的前列腺增生症患者308例,与同期在我院体检发现前列腺增生而没有服用任何药物的健康体检者330例进行比较,3年期间主要观察前列腺体积、临床症状评分、残余尿、尿流率变化、以及尿潴留、血尿的发生率。结果服用保列治3年后前列腺体积缩小12.6%,最大尿流率增加3.5 mL/s,国际前列腺评分下降4.5分,残余尿量下降20 mL。本组患者无尿潴留、无前列腺源性血尿发生。结论中长期服用保列治5 mg qd的前列腺增生症患者能使前列腺体积逐渐缩小,改善最大尿流率,减少了尿潴留和前列腺源性血尿的发生率。

Clinical Effects of Long-term Use of Finasteride in Treatment of Patients with Benign Prostatic Hyperplasia

Objective To evaluate the clinical efficacy of long-term use of finasteride in the treatment of patients with benign prostatic hyperplasia（BPH）. Methods Observation alone taking Proscar 5 mg qd and more than 3 years 308 cases of benign prostatic hyperplasia in patients with the same period in our hospital examination found benign prostatic hyperplasia without taking any drugs healthy 330 cases were compared, the main observation period of 3 years prostate volume, clinical symptom score, residual urine, urinary flow rate changes, and urinary retention, hematuria incidence. Results Taking Proscar prostate volume reduction after three years of 12.6%, increase in maximum urinary flow rate 3.5 mL / s, International Prostate score decreased 4.5 points, residual urine volume decreased 20 mL. This group of patients without urinary retention, hematuria occurred without prostate. Conclusions Term taking Proscar 5 mg qd in patients with benign prostatic hyperplasia can gradually reduced prostate volume, Qmax improvement, reduced the incidence of urinary retention and prostate hematuria.